(NASDAQ: VIOT) Company Presentation Safe Harbor Statement This presentation has been prepared by Viomi Technology Co., Ltd ("Viomi" or the "Company") solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. This docu ...

Ironwood Pharmaceuticals Q3 2025 Investor Update November 10, 2025 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mission; our strategy, business, financial position and operations; our ability to drive growth and profitability; the commercial potential of LI ...

Digital Driving Robust Growth Direct Digital Revenues Up 63% YoY Robust Revenue and EBITDA momentum 10 November 2025 | 3Q25 Results Presentation DISCLAIMER AND NOTICE TO READERS VEON's results and other financial information presented in this document are, unless otherwise stated, prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the international Accounting Standards Board and have not been externally reviewed and/or audited. These figures are preliminary and sub ...

Investor Presentation Where Intelligence Meets Infrastructure® November 11, 2025 Non-GAAP Measures In an effort to provide investors with additional information regarding the Company's results as determined by accounting principles generally accepted in the United States ("GAAP"), the Company also provides non-GAAP information that management believes is useful to investors. These non-GAAP measures have limitations as analytical tools, and securities analysts, investors and other interested parties should n ...

Investor Presentation (NASDAQ: CBAT) Technology, Inc. November 2025 CBAK Energy ©2025 CBAK. All Rights Reserved. The First Chinese Li-ion Battery Manufacturer Listed in NASDAQ Disclaimer Powering a Sustainable Life with Electricity Disclaimers and Other Important Information This presentation (the "Presentation") about CBAK Energy Technology, Inc. (the "Company" or "CBAK") is dated as of March 2021. It is information in a summary form and does not purport to be complete. The data contained herein is derived ...

NYSE : SLI | TSX.V : SLI The Future of Lithium in North America Creating a Leading U.S. Lithium Business November 2025 www.standardlithium.com Cautionary Statement This presentation and the information contained herein or provided orally in connection herewith is provided for the exclusive use of the recipients and may not be reproduced, provided or disclosed to others, or used for any other purpose, without the written authorization of Standard Lithium Ltd. (the "Company", "Standard Lithium" or "SLI"). Thi ...

Merck & Co (NYSE:MRK) Update / Briefing November 09, 2025 07:01 PM ET Speaker0Welcome to the Merkin Co. Incorporated, Rawlway, New Jersey, USA Investor Event. At this time, all participants are in a listen only mode until the question and answer session of today's conference. This call is being recorded. If you have any objections, you may disconnect at this time.I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.Speaker1Thank you, I ...

American Heart Association 2025 Investor Presentation November 9, 2025 Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. ...

Vertex Pharmaceuticals Update Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Event**: Update on Vertex Kidney programs during the American Society of Nephrology, Kidney Week 2024-2025 [1][4] Key Points on Kidney Programs - Vertex is focusing on four renal diseases: IgA nephropathy, membranous nephropathy, AMKD, and ADPKD, which are in mid to late-stage development [5][6] - The company emphasizes a research strategy centered on unmet medical needs and validated targets [6] - The Rainier phase III study of povatacicept in IgA nephropathy completed enrollment in less than 15 months, marking it as the fastest contemporary study for this condition [6][7] - The membranous nephropathy trial is currently underway, and the ADPKD study is in phase II development [8][9] Clinical Data Highlights - **IgA Nephropathy**: - The Ruby3 trial showed a 64% reduction in urinary protein levels over 48 weeks [25][31] - A significant increase in GFR of +3.3 mL/min/m² was observed, which is considered unprecedented [26][31] - 53% of patients achieved clinical remission, defined as less than 500 mg of protein in 24 hours [31] - **Membranous Nephropathy**: - The trial showed an 82% reduction in proteinuria over 48 weeks [29][31] - 100% of patients achieved immunologic remission by week 48 [30][31] Drug Mechanism and Administration - **Povatacicept**: - Designed as a dual APRIL-BAFF inhibitor, it targets B-cell maturation and is engineered for high tissue distribution [11][12] - Expected to be administered at home via an autoinjector every four weeks [12] Regulatory Outlook - Vertex anticipates filing the first module for povatacicept by the end of the year, with a complete filing expected in the first half of next year [14][15] Industry Context and Guidelines - The KDIGO guidelines have evolved to recognize IgA nephropathy as a serious condition requiring proactive treatment [40][41] - New guidelines emphasize the importance of reducing proteinuria and intervening in the pathologic processes of IgA nephropathy [42][43] - The partnership between the FDA and nephrology experts aims to expedite drug development for IgA nephropathy [43] Future Directions - Vertex is exploring additional indications for povatacicept, including myasthenia gravis [12][13] - The company is committed to addressing both chronic kidney disease and the immunologic aspects of IgA nephropathy simultaneously [46][47] Conclusion - Vertex Pharmaceuticals is positioned as a leader in developing innovative treatments for kidney diseases, with promising clinical data supporting the efficacy of povatacicept in IgA and membranous nephropathy, and a strategic focus on addressing unmet medical needs in renal medicine [5][6][31]

Kidney Program Updates at the American Society of Nephrology Kidney Week 2025 November 8, 2025 ©2025 Vertex Pharmaceuticals Incorporated ©2025 Vertex Pharmaceuticals Incorporated Presentation intended for the investment community Agenda Welcome Susie Lisa, CFA, Senior Vice President, Investor Relations, Vertex Pharmaceuticals Kidney portfolio Reshma Kewalramani, M.D., President and Chief Executive Officer, Vertex Pharmaceuticals RUBY-3 late breaking data recap James A. Tumlin, M.D., Professor of Medicine in ...